Sandoz Group AG

The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.

United Therapeutics found liable for breaching 2015 agreement with Sandoz, resolving patent dispute; court ruled in favor of Sandoz Inc.

Regeneron accuses Sandoz of patent infringement on Eylea and BPCIA violations, alleging Sandoz withheld critical info during biosimilar approval.

Court finds United Therapeutics' interference with generic Treprostinil Injection launch caused over $137 million in losses; proceeds from litigation to be split equally between Sandoz and Liquidia PAH, with Liquidia PAH's share further divided between Henderson SPV and PBM RG Holdings.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

FDA approves Enzeevu (aflibercept-abzv), a biosimilar to Eylea, for intravitreal injection in patients with neovascular age-related macular degeneration (nAMD). Enzeevu is a key biosimilar value driver for Sandoz, extending its leading US ophthalmology portfolio. The approval is based on comprehensive analytical, preclinical, and clinical data from the Mylight study.

FDA approves Sandoz's biosimilar Pyzchiva® (ustekinumab-ttwe), developed by Samsung Bioepis, for all indications of Stelara®, including treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Pyzchiva® is set to launch in the US in February 2025, aiming to provide affordable biosimilar alternatives for patients.